Photo from agenusbio.com
Jul 1, 2023, 06:00
Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer
In a post by Agenus on Linkedin, it says, “ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer.
Median overall survival of 20.9 months for patients without active liver metastases surpasses the recently reported 12.9-month benchmark with standard of care in this population.”
For details: Click here
Source: Agenus/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48